https://www.psychiatryadvisor.com/home/schizophrenia-advisor/second-generation-antipsychotics-as-targeted-treatment-in-schizophrenia/
Treatment with different second-generation antipsychotic agents, including risperidone, olanzapine, quetiapine, and aripiprazole, is associated with differing profiles of 5-HT2A and 5-HT6 receptor availability. A first-of-its-kind in vivo study was conducted in men to examine 5-HT2A and 5-HT6 receptor availability in patients with schizophrenia who were receiving chronic treatment with a second-generation antipsychotic agent compared with unmedicated, age-matched healthy male controls. Results of the analysis were published in the journal Psychiatry Research: Neuroimaging .
I’ve no idea what any of this story means.
1 Like
Haha this is all going right over my poor brain.
1 Like
Are you asking about the content of this article or about its consequences for treatment?
“Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors”
I got that from another article.
I think 11C-GSK215083 is a measurement of how well the medications bind to the 5HT6 and 5HT2A Receptors. Both of those are serotonin receptor.
The study says that each medication binds to those receptors more or less frequently in different parts of the brain.
So I think the implication is that they may actually have a target when administering antipsychotics.
So the whole experience for psychiatric patients may be becoming less lab ratish lol
There where 18 people in the study though.
And there’s quite a bit I’m not clear on.
Like I have no idea how they determine where an individual is deficient.
2 Likes
Also they suggest that for add ons of medications targeting 5HT6 receptors, they may not be very useful when the primary med is olanzapine.
2 Likes
